Vir Biotechnology, Inc.·4

Aug 10, 4:50 PM ET

Virgin Herbert 4

4 · Vir Biotechnology, Inc. · Filed Aug 10, 2022

Insider Transaction Report

Form 4
Period: 2022-08-09
Virgin Herbert
EVP, Research & CSO
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-08-097,916125,416 total
    Exercise: $10.39Exp: 2029-07-12Common Stock (7,916 underlying)
  • Exercise/Conversion

    Common Stock

    2022-08-09$1.53/sh+70,177$107,371254,584 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-08-0970,177140,328 total
    Exercise: $1.53Exp: 2028-01-26Common Stock (70,177 underlying)
  • Exercise/Conversion

    Common Stock

    2022-08-09$10.39/sh+7,916$82,287262,500 total
Footnotes (2)
  • [F1]The option is fully vested and exercisable.
  • [F2]1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION